These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19208845)

  • 1. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
    Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
    Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y; Bejarano MT; Zaias J; Merchan JR
    Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
    Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic measles virus retargeting by ligand display.
    Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
    Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.
    Jing Y; Chavez V; Khatwani N; Ban Y; Espejo AP; Chen X; Merchan JR
    Cancer Gene Ther; 2020 Dec; 27(12):910-922. PubMed ID: 32231231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
    Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E
    Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
    Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
    Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
    Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
    Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
    Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
    Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
    Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
    Ayala-Breton C; Barber GN; Russell SJ; Peng KW
    Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
    Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
    Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
    Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
    Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.